UBS Group
RPRX icon

UBS Group’s Royalty Pharma RPRX Stock Holding History

UBS Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176M Buy
3,143,347
+1,331,144
+73% +$69.3M 0.02% 738
2026
Q1 		$86.9M Sell
1,812,203
-193,628
-10% -$8.48M 0.01% 1158
2025
Q4 		$77.5M Buy
2,005,831
+464,233
+30% +$17.7M 0.01% 1225
2025
Q3 		$54.4M Sell
1,541,598
-665,167
-30% -$24.1M 0.01% 1541
2025
Q2 		$79.5M Buy
2,206,765
+854,289
+63% +$28.3M 0.01% 1134
2025
Q1 		$42.1M Sell
1,352,476
-353,046
-21% -$11.2M 0.01% 1635
2024
Q4 		$43.5M Buy
1,705,522
+88,037
+5% +$2.33M 0.01% 1590
2024
Q3 		$45.8M Buy
1,617,485
+332,365
+26% +$9.21M 0.01% 1204
2024
Q2 		$33.9M Buy
1,285,120
+585,185
+84% +$16.2M 0.01% 1297
2024
Q1 		$21.3M Sell
699,935
-167,060
-19% -$4.92M 0.01% 1637
2023
Q4 		$24.4M Buy
866,995
+122,555
+16% +$3.37M 0.01% 1452
2023
Q3 		$20.2M Buy
744,440
+54,697
+8% +$1.62M 0.01% 1473
2023
Q2 		$21.2M Buy
689,743
+187,788
+37% +$6.36M 0.01% 1411
2023
Q1 		$18.1M Sell
501,955
-233,230
-32% -$8.65M 0.01% 1478
2022
Q4 		$29.1M Buy
735,185
+243,324
+49% +$10.2M 0.01% 1158
2022
Q3 		$19.8M Buy
491,861
+294,062
+149% +$12.6M 0.01% 1286
2022
Q2 		$8.32M Sell
197,799
-279,890
-59% -$11.5M ﹤0.01% 1954
2022
Q1 		$18.6M Buy
477,689
+26,579
+6% +$1.04M 0.01% 1479
2021
Q4 		$18M Buy
451,110
+159,970
+55% +$6.21M 0.01% 1659
2021
Q3 		$10.5M Sell
291,140
-378,404
-57% -$14.7M ﹤0.01% 1981
2021
Q2 		$27.4M Buy
669,544
+225,011
+51% +$9.57M 0.01% 1245
2021
Q1 		$19.4M Buy
444,533
+221,447
+99% +$10.5M 0.01% 1468
2020
Q4 		$11.2M Buy
223,086
+169,536
+317% +$7.19M ﹤0.01% 1764
2020
Q3 		$2.25M Buy
53,550
+44,649
+502% +$1.92M ﹤0.01% 2938
2020
Q2 		$432K Buy
+8,901
New +$441K ﹤0.01% 4264

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's RPRX Position: Q2 2026 in Review

UBS Group increased its Royalty Pharma (RPRX) stake by 73% in Q2 2026, buying an estimated $69.3M and bringing the position to 3,143,347 shares worth $176M. The position accounts for 0.02% of the portfolio, ranked #738.

UBS Group first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • UBS Group held 3,143,347 shares of Royalty Pharma worth $176M as of Q2 2026.
  • UBS Group bought 1,331,144 Royalty Pharma shares in Q2 2026, an estimated $69.3M.
  • Royalty Pharma made up 0.02% of UBS Group's portfolio in Q2 2026, its #738 holding.
  • UBS Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.